Log In Sign up
The largest database of trusted experimental protocols
> Chemicals & Drugs > Organic Chemical > Lipid Nanoparticles

Lipid Nanoparticles

Lipid nanoparticles are a versatile class of nanomaterials that have gained significant attention in drug delivery, therapeutics, and biomedical applications.
These nanostructures, typically ranging from 50 to 200 nanometers in size, are composed of lipids arranged in a unique bilayer configuration.
Lipid nanoparticles offer numerous advantages, such as improved drug solubility, enhanced bioavailability, and targeted delivery to specific tissues or cells.
Additionally, they can protect sensitive cargo, such as RNA or DNA, from degradation and facilitate their efficient intracellular uptake.
Reseach on lipid nanoparticles continues to evolve, with scientists exploring new formulations, surface modifications, and innovative applications to unlock their full potential.
PubCompare.ai's AI-driven protocol comparison platform can help streamline your lipid nanoparticle optimization effortlessly, allowing you to identify the best protocols from literature, preprints, and patents to advance your research.

Most cited protocols related to «Lipid Nanoparticles»

1
Sequence-optimized SARS-CoV-2 S-2P mRNA Vaccine
Cited 15 times
A sequence-optimized mRNA encoding prefusion-stabilized SARS-CoV-2 S-2P protein was synthesized in vitro using an optimized T7 RNA polymerase-mediated transcription reaction with complete replacement of uridine by N1m-pseudouridine34 . The reaction included a DNA template containing the immunogen open-reading frame flanked by 5’ UTR and 3’ UTR sequences and was terminated by an encoded polyA tail. After transcription, the Cap 1 structure was added to the 5’ end using Vaccinia capping enzyme (New England Biolabs) and Vaccinia 2’O-methyltransferase (New England Biolabs). The mRNA was purified by oligo-dT affinity purification, buffer exchanged by tangential flow filtration into sodium acetate, pH 5.0, sterile filtered, and kept frozen at −20 °C until further use.
The mRNA was encapsulated in a lipid nanoparticle through a modified ethanol-drop nanoprecipitation process described previously20 (link). Briefly, ionizable, structural, helper, and PEG lipids were mixed with mRNA in acetate buffer, pH 5.0, at a ratio of 2.5:1 (lipids:mRNA). The mixture was neutralized with Tris-Cl, pH 7.5, sucrose was added as a cryoprotectant, and the final solution was sterile filtered. Vials were filled with formulated LNP and stored frozen at −70 °C until further use. The drug product underwent analytical characterization, which included the determination of particle size and polydispersity, encapsulation, mRNA purity, double stranded RNA content, osmolality, pH, endotoxin, and bioburden, and the material was deemed acceptable for in vivo study.
Corbett K.S., Edwards D.K., Leist S.R., Abiona O.M., Boyoglu-Barnum S., Gillespie R.A., Himansu S., Schäfer A., Ziwawo C.T., DiPiazza A.T., Dinnon K.H., Elbashir S.M., Shaw C.A., Woods A., Fritch E.J., Martinez D.R., Bock K.W., Minai M., Nagata B.M., Hutchinson G.B., Wu K., Henry C., Bahi K., Garcia-Dominguez D., Ma L., Renzi I., Kong W.P., Schmidt S.D., Wang L., Zhang Y., Phung E., Chang L.A., Loomis R.J., Altaras N.E., Narayanan E., Metkar M., Presnyak V., Liu C., Louder M.K., Shi W., Leung K., Yang E.S., West A., Gully K.L., Stevens L.J., Wang N., Wrapp D., Doria-Rose N.A., Stewart-Jones G., Bennett H., Alvarado G.S., Nason M.C., Ruckwardt T.J., McLellan J.S., Denison M.R., Chappell J.D., Moore I.N., Morabito K.M., Mascola J.R., Baric R.S., Carfi A, & Graham B.S. (2020). SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness. Nature, 586(7830), 567-571.
Publication 2020
3' Untranslated Regions Acetate Antigens bacteriophage T7 RNA polymerase Buffers Chromatography, Affinity Cryoprotective Agents DNA, A-Form Endotoxins Enzymes Ethanol Filtration Freezing Lipid Nanoparticles Lipids Methyltransferase oligo (dT) Pharmaceutical Preparations Poly(A) Tail Proteins RNA, Double-Stranded RNA, Messenger SARS-CoV-2 Sodium Acetate Strains Sucrose TRAF3 protein, human Transcription, Genetic Tromethamine Uridine Vaccinia virus
2
Moderna's mRNA-1273 Vaccine Formulation
Cited 7 times
The mRNA-1273 vaccine candidate, manufactured by Moderna, encodes the S-2P antigen, consisting of the SARS-CoV-2 glycoprotein with a transmembrane anchor and an intact S1–S2 cleavage site. S-2P is stabilized in its prefusion conformation by two consecutive proline substitutions at amino acid positions 986 and 987, at the top of the central helix in the S2 subunit.8 (link) The lipid nanoparticle capsule composed of four lipids was formulated in a fixed ratio of mRNA and lipid. The mRNA-1273 vaccine was provided as a sterile liquid for injection at a concentration of 0.5 mg per milliliter. Normal saline was used as a diluent to prepare the doses administered.
Jackson L.A., Anderson E.J., Rouphael N.G., Roberts P.C., Makhene M., Coler R.N., McCullough M.P., Chappell J.D., Denison M.R., Stevens L.J., Pruijssers A.J., McDermott A., Flach B., Doria-Rose N.A., Corbett K.S., Morabito K.M., O’Dell S., Schmidt S.D., Swanson PA I.I., Padilla M., Mascola J.R., Neuzil K.M., Bennett H., Sun W., Peters E., Makowski M., Albert J., Cross K., Buchanan W., Pikaart-Tautges R., Ledgerwood J.E., Graham B.S, & Beigel J.H. (2020). An mRNA Vaccine against SARS-CoV-2 — Preliminary Report. The New England Journal of Medicine.
Publication 2020
Amino Acid Substitution Antigens Capsule Cytokinesis Glycoproteins Helix (Snails) Lipid Nanoparticles Lipids mRNA Vaccine Normal Saline Proline Protein Subunits RNA, Messenger SARS-CoV-2 Sterility, Reproductive
3
Cold Dilution Microemulsion for Solid Lipid Nanoparticles
Cited 7 times
SLNs were prepared by the method named “cold dilution of microemulsion” [17 (link)]; briefly, a preliminary screening on several compositions was performed, operating at room temperature, to obtain the suitable O/W µE whose disperse phase consisted in a solution of a solid lipid dissolved in a partially water miscible solvent. The solvent and the external phase, consisting of water, were mutually saturated at 25 ± 2 °C for 2 h in order to ensure the initial thermodynamic equilibrium of both liquids, before using them in µE formulation. Lipid nanoparticles were precipitated by quickly adding 5 mL of water into the µE (1 mL) to remove the solvent from the disperse phase and extract it into the continuous phase.
µEs were obtained with biocompatible GRAS ingredients (Generally Recognized As Safe). Among different lipids tested (TL, trimyristin, tristearin, myristic acid, glyceryl dibehenate, and glyceryl monostearate), a TL solution in EA was chosen as oil phase, because of its highest solubility in this partially water-miscible solvent (Table 1). EA and water were mutually pre-saturated before using them in µE preparation (EAs and Ws respectively). BenzOH, TA, BL were also tested as partially water-miscible solvents (water saturated) to solubilize the lipid.
Epikuron® 200 was chosen as surfactant together with polysorbate (20, 40, 80) or Cremophor® RH 60 at 3:1 w/w constant ratio.
Na TdC, Na TC, Na GC, Na C were tested as co-surfactants, BenzOH was chosen as a co-solvent.
A formulation study was performed varying the percentages of surfactant and co-surfactant/co-solvent. The optimal µE formulation, in the absence of any drug, called µE1, is reported in Table 2.
µE1 (1 mL) was then diluted with a 2% w/w polymeric aqueous solution (5 mL) to precipitate SLNs. In order to avoid SLN aggregation [16 (link)], different polymers (Cremophor® RH60, Pluronic® F68, PVA® 9000, PVA® 14000) and different percentages of Pluronic® F68 were tested to check the best conditions to obtain small and non-aggregated SLNs. Probably, the polymer disposition on SLN surface influences surface hydrophilicity and charge. A formulation study was then performed to optimize SLN size.
Chirio D., Peira E., Dianzani C., Muntoni E., Gigliotti C.L., Ferrara B., Sapino S., Chindamo G, & Gallarate M. (2019). Development of Solid Lipid Nanoparticles by Cold Dilution of Microemulsions: Curcumin Loading, Preliminary In Vitro Studies, and Biodistribution. Nanomaterials, 9(2), 230.
Full text: Click here
Publication 2019
Cold Temperature cremophor Glucocorticoid-Remediable Aldosteronism glyceryl behenate glyceryl monostearate Lipid A Lipid Nanoparticles Lipids Myristic Acid Pharmaceutical Preparations Pluronic F68 Polymers Polysorbates Solvents Surface-Active Agents Surfactants Technique, Dilution trimyristin tristearin
4
Sera Evaluation of COVID-19 Vaccine Efficacy
Cited 4 times

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2021
2019-nCoV Vaccine mRNA-1273 Communicable Diseases COVID-19 Vaccines COVID 19 HIV Vaccine Lipid Nanoparticles Matrix-M mRNA Vaccine Novavax vaccine Pharmaceutical Adjuvants SARS-CoV-2 SARS-CoV-2 D614G variant Serum spike protein, SARS-CoV-2 Vaccination Vaccines
5
Moderna SARS-CoV-2 mRNA-1273 Vaccine
Cited 4 times
The mRNA-1273 vaccine was codeveloped by researchers at the NIAID Vaccine Research Center and Moderna in Cambridge, Massachusetts. This vaccine encodes a stabilized version of the SARS-CoV-2 full-length spike glycoprotein trimer, S-2P, which has been modified to include two proline substitutions at the top of the central helix in the S2 subunit. The mRNA is encapsulated in lipid nanoparticles at a concentration of 0.5 mg per milliliter and diluted with normal saline to achieve the final target vaccine concentrations.
Anderson E.J., Rouphael N.G., Widge A.T., Jackson L.A., Roberts P.C., Makhene M., Chappell J.D., Denison M.R., Stevens L.J., Pruijssers A.J., McDermott A.B., Flach B., Lin B.C., Doria-Rose N.A., O’Dell S., Schmidt S.D., Corbett K.S., Swanson PA I.I., Padilla M., Neuzil K.M., Bennett H., Leav B., Makowski M., Albert J., Cross K., Edara V.V., Floyd K., Suthar M.S., Martinez D.R., Baric R., Buchanan W., Luke C.J., Phadke V.K., Rostad C.A., Ledgerwood J.E., Graham B.S, & Beigel J.H. (2020). Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults. The New England Journal of Medicine.
Publication 2020
Helix (Snails) Lipid Nanoparticles mRNA Vaccine Normal Saline Proline Protein Subunits RNA, Messenger spike protein, SARS-CoV-2 Vaccines

Most recents protocols related to «Lipid Nanoparticles»

1
Immunogenicity of Betacoronavirus mRNA Vaccines
Not available on PMC !

Example 20

The instant study is designed to test the immunogenicity in rabbits of candidate betacoronavirus (e.g., MERS-CoV, SARS-CoV, HCoV-OC43, HCoV-229E, HCoV-NL63, HCoV-NL, HCoV-NH or HCoV-HKU1 or a combination thereof) vaccines comprising a mRNA polynucleotide encoding the spike (S) protein, the S1 subunit (S1) of the spike protein, or the S2 subunit (S2) of the spike protein obtained from a betacoronavirus (e.g., MERS-CoV, SARS-CoV, HCoV-OC43, HCoV-229E, HCoV-NL63, HCoV-NL, HCoV-NH or HCoV-HKU1).

Rabbits are vaccinated on week 0 and 3 via intravenous (IV), intramuscular (IM), or intradermal (ID) routes. One group remains unvaccinated and one is administered inactivated betacoronavirus. Serum is collected from each rabbit on weeks 1, 3 (pre-dose) and 5. Individual bleeds are tested for anti-S, anti-S1 or anti-S2 activity via a virus neutralization assay from all three time points, and pooled samples from week 5 only are tested by Western blot using inactivated betacoronavirus (e.g., inactivated MERS-CoV, SARS-CoV, HCoV-OC43, HCoV-229E, HCoV-NL63, HCoV-NL, HCoV-NH or HCoV-HKU1).

In experiments where a lipid nanoparticle (LNP) formulation is used, the formulation may include a cationic lipid, non-cationic lipid, PEG lipid and structural lipid in the ratios 50:10:1.5:38.5. The cationic lipid is DLin-KC2-DMA (50 mol %) or DLin-MC3-DMA (50 mol %), the non-cationic lipid is DSPC (10 mol %), the PEG lipid is PEG-DOMG (1.5 mol %) and the structural lipid is cholesterol (38.5 mol %), for example.

US11872278B2. Combination HMPV/RSV RNA vaccines (2024-01-16). ModernaTX, Inc. [US]. Inventors: Giuseppe Ciaramella [US], Sunny Himansu [US].
Full text: Click here
Patent 2024
Antigens Betacoronavirus Biological Assay Cations Cholesterol Coronavirus 229E, Human Coronavirus OC43, Human Hemorrhage Human coronavirus HKU1 Lipid Nanoparticles Lipids Middle East Respiratory Syndrome Coronavirus M protein, multiple myeloma NL63, Human Coronavirus Oryctolagus cuniculus Polynucleotides Protein Subunits Rabbits RNA, Messenger Serum Severe acute respiratory syndrome-related coronavirus spike protein, SARS-CoV-2 Vaccines Virus Physiological Phenomena
2
Optimizing Dendrimer Nanoparticles for siRNA Delivery
Not available on PMC !

Example 8

To evaluate which lipid composition within the dendrimer nanoparticles lead to improved siRNA delivery, the identity and concentration of different phospholipids and PEG-lipids were varied. Three different cell lines (HeLa-Luc, A549-Luc, and MDA-MB231-Luc) were used. The cells were present at 10K cells per well and a 24 hour incubation. The readout was determined 24 hours post transfection. In the nanoparticles, DSPC and DOPE were used as phospholipids and PEG-DSPE, PEG-DMG, and PEG-DHD were used as PEG-lipids. The compositions contain a lipid or dendrimer:cholesterol:phospholipid:PEG-lipid mole ratio of 50:38:10:2. The mole ratio of lipid/dendrimer to siRNA was 100:1 with 100 ng dose being used. The RiboGreen, Cell-titer Fluor, and OneGlo assays were used to determine the effectiveness of these compositions. Results show the relative luciferase activity in HeLa-Luc cells (FIG. 17A), A549-Luc (FIG. 17B), and MDA-MB231-Luc (FIG. 17C). The six formulations used in the studies include: dendrimer (lipid)+cholesterol+DSPC+PEG-DSPE (formulation 1), dendrimer (lipid)+cholesterol+DOPE+PEG-DSPE (formulation 2), dendrimer (lipid)+cholesterol+DSPC+PEG-DMG (formulation 3), dendrimer (lipid)+cholesterol+DOPE+PEG-DMG (formulation 4), dendrimer (lipid)+cholesterol+DSPC+PEG-DSPE (formulation 5), and dendrimer (lipid)+cholesterol+DOPE+PEG-DHD (formulation 6).

Further experiments were run to determine which phospholipids showed the increased delivery of siRNA molecules. A HeLa-Luc cell line was used with 10K cells per well, 24 hour incubation, and readout 24 hours post transfections. The compositions contained either DOPE or DOPC as the phospholipid with PEG-DHD as the PEG-lipid. The ratio of lipid (or dendrimer):cholesterol:phospholipid:PEG-lipid was 50:38:10:2 in a mole ratio with the mole ratio of dendrimer (or lipid) to siRNA of 200:1. These compositions was tested at a 50 ng dose using the Cell-titer Fluor and OneGlo assays. These results are shown in FIGS. 18A & 18B.

US11858884B2. Compositions and methods for modulating gene or gene product in cells (2024-01-02). The Board of Regents of The University of Texas System [US]. Inventors: Daniel J. Siegwart [US], Kejin Zhou [US].
Full text: Click here
Patent 2024
1,2-oleoylphosphatidylcholine Biological Assay Cell Lines Cells Cholesterol Dendrimers Figs HeLa Cells Lipid Nanoparticles Lipids Luciferases Nevus Obstetric Delivery Phospholipids polyethylene glycol-distearoylphosphatidylethanolamine RNA, Small Interfering Transfection
3
Evaluation of mRNA-based hMPV Vaccines
Not available on PMC !

Example 13

The instant study is designed to test the efficacy in cotton rats of candidate hMPV vaccines against a lethal challenge using an hMPV vaccine comprising mRNA encoding Fusion (F) glycoprotein, major surface glycoprotein G, or a combination of both antigens obtained from hMPV. Cotton rats are challenged with a lethal dose of the hMPV.

Animals are immunized intravenously (IV), intramuscularly (IM), or intradermally (ID) at week 0 and week 3 with candidate hMPV vaccines with and without adjuvant. Candidate vaccines are chemically modified or unmodified. The animals are then challenged with a lethal dose of hMPV on week 7 via IV, IM or ID. Endpoint is day 13 post infection, death or euthanasia. Animals displaying severe illness as determined by >30% weight loss, extreme lethargy or paralysis are euthanized. Body temperature and weight are assessed and recorded daily.

In experiments where a lipid nanoparticle (LNP) formulation is used, the formulation may include a cationic lipid, non-cationic lipid, PEG lipid and structural lipid in the ratios 50:10:1.5:38.5. The cationic lipid is DLin-KC2-DMA (50 mol %) or DLin-MC3-DMA (50 mol %), the non-cationic lipid is DSPC (10 mol %), the PEG lipid is PEG-DOMG (1.5 mol %) and the structural lipid is cholesterol (38.5 mol %), for example.

US11872278B2. Combination HMPV/RSV RNA vaccines (2024-01-16). ModernaTX, Inc. [US]. Inventors: Giuseppe Ciaramella [US], Sunny Himansu [US].
Full text: Click here
Patent 2024
Animals Antigens Body Temperature Cations Cholesterol Euthanasia Glycoproteins Human Metapneumovirus Infection Lethargy Lipid Nanoparticles Lipids Membrane Glycoproteins Pharmaceutical Adjuvants Rats, Cotton RNA, Messenger Rodent Vaccines
4
Optimizing CRISPR-Cas9 for Hepatocyte Editing
Not available on PMC !

Example 95

After testing the different strategies for HDR gene editing, the lead CRISPR-Cas9/DNA donor combinations will be re-assessed in primary human hepatocytes for efficiency of deletion, recombination, and off-target specificity. Cas9 mRNA or RNP will be formulated into lipid nanoparticles for delivery, sgRNAs will be formulated into nanoparticles or delivered as AAV, and donor DNA will be formulated into nanoparticles or delivered as AAV.

US11866727B2. Materials and methods for treatment of glycogen storage disease type 1A (2024-01-09). CRISPR THERAPEUTICS AG [None]. Inventors: Chad Albert Cowan [US], Roman Lvovitch Bogorad [US], Ante Sven Lundberg [US], Kirsten Leah Beaudry [US].
Full text: Click here
Patent 2024
Clustered Regularly Interspaced Short Palindromic Repeats Deletion Mutation Hepatocyte Homo sapiens Lipid Nanoparticles Obstetric Delivery Recombination, Genetic RNA, Messenger Tissue Donors
5
Evaluating DsiRNA Knockdown of HAO1 in Primary Hyperoxaluria
Not available on PMC !

Example 4

The ability of certain, active HAO1-targeting DsiRNAs to reduce HAO1 levels within the liver of a mouse was examined. DsiRNAs employed in the study were: HAO1-1105, HAO1-1171, HAO1-1221, HAO1-1272, HAO1-1273, HAO1-1316, HAO1-1378 and HAO1-1379, each of which were synthesized with passenger (sense) strand modification pattern “SM107” and guide (antisense) strand modification pattern “M48” (patterns described above). To perform the study, a primary hyperoxaluria model was generated through oral gavage of 0.25 mL of 0.5 M glycolate to cause urine oxalate accumulation in C57BL/6 female mice. Animals were randomized and assigned to groups based on body weight. Intravenous dosing of animals with lipid nanoparticles (LNPs; here, an LNP formulation named EnCore-2345 was employed) containing 1 mg/kg or 0.1 mg/kg of DsiRNA was initiated on day 0. Dosing continued BIW for a total of three doses in mice prior to glycolate challenge. Four hour and 24 h urine samples were collected after glycolate challenge for assessment of oxalate/creatinine levels (see FIG. 4 for experimental flow chart). Animals were then sacrificed at 24 hrs after glycolate challenge. Liver was dissected and weighed, and HAO1 levels were assessed using RT-qPCR, ViewRNA, western blot for glycolate oxidase and/or glycolate oxidase immunohistochemistry (ViewRNA, western blot for glycolate oxidase and glycolate oxidase immunohistochemistry data not shown). Serum samples were also subjected to ELISA for detection of glycolate oxidase (data not shown). Notably, all eight DsiRNAs showed robust knockdown of HAO1 when administered at 1 mg/kg (FIG. 5). At least two (HAO1-1171 and HAO1-1378) of the eight DsiRNAs tested in vivo also showed robust knockdown of HAO1 in all treated animals when administered at 0.1 mg/kg. As shown in FIG. 5, administration of the HAO1-1171-M107/M48 DsiRNA at 0.1 mg/kg caused an average knockdown of 70% in liver tissue of treated mice, while administration at 1 mg/kg produced an average knockdown of 97% in liver tissue of treated mice. Similarly, administration of the HAO1-1378-M107/M48 DsiRNA at 0.1 mg/kg caused an average knockdown of 53% in liver tissue of treated mice, while administration at 1 mg/kg produced an average knockdown of 97% in liver tissue of treated mice. HAO-1171-induced knockdown at both 0.1 mg/kg and 1 mg/kg was further confirmed by ViewRNA in situ hybridization assays.

Robust levels of HAO1 mRNA knockdown were observed in liver tissue of mice treated with 1 mg/kg amounts of HAO1-targeting DsiRNAs HAO1-1171 and HAO1-1378 (FIG. 6 and data not shown), and even 0.1 mg/kg amounts of these HAO1-targeting DsiRNAs produced robust HAO1 knockdown. As shown in FIG. 6, single dose HAO1-1171 DsiRNA treatment achieved durable HAO1 mRNA target knockdown for at least 120 hours post-administration in the liver of treated animals. While robust HAO1 knockdown was achieved in liver, initial glycolate challenge experiments yielded inconclusive phenotypic results (data not shown).

In additional in vivo experiments, both HAO1 and oxalate levels were assessed in both control- and DsiRNA-treated genetically engineered PH1 model mice.

US11873493B2. Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA (2024-01-16). Dicerna Pharmaceuticals, Inc. [US]. Inventors: Bob D. Brown [US], Henryk T. Dudek [US].
Full text: Click here
Patent 2024
Animals Biological Assay Body Weight Creatinine Enzyme-Linked Immunosorbent Assay Females Glycolates glycollate oxidase Immunohistochemistry In Situ Hybridization Lipid Nanoparticles Liver Mice, House Mice, Inbred C57BL Oxalates Phenotype Primary Hyperoxaluria RNA, Messenger Serum Tissues Tube Feeding Urine Western Blot

Top products related to «Lipid Nanoparticles»

1
Zetasizer nano z by Malvern Panalytical
Sourced in United Kingdom, Germany, United States, France, Japan, China, Netherlands, Morocco, Spain, Cameroon
The Zetasizer Nano ZS is a dynamic light scattering (DLS) instrument designed to measure the size and zeta potential of particles and molecules in a sample. The instrument uses laser light to measure the Brownian motion of the particles, which is then used to calculate their size and zeta potential.
2
Cholesterol by Merck Group
Sourced in United States, Germany, United Kingdom, India, Japan, Sao Tome and Principe, China, France, Spain, Canada, Switzerland, Italy, Australia, Israel, Brazil, Belgium, Poland, Hungary, Macao
Cholesterol is a lab equipment product that measures the concentration of cholesterol in a given sample. It provides quantitative analysis of total cholesterol, HDL cholesterol, and LDL cholesterol levels.
3
Amicon ultra centrifugal filter by Merck Group
Sourced in United States, Germany, Ireland, United Kingdom, Morocco, Australia, France, Japan
Amicon Ultra centrifugal filters are laboratory devices used for the concentration and purification of macromolecules, such as proteins, nucleic acids, and other biological samples, through the process of ultrafiltration. These filters feature a selective membrane that allows the passage of smaller molecules while retaining the desired larger molecules. The core function of Amicon Ultra centrifugal filters is to separate and concentrate target analytes from complex mixtures efficiently.
4
Nanoassemblr ignite by Precision Nanosystems
Sourced in Canada
The NanoAssemblr Ignite is a microfluidic-based platform for the formulation of lipid nanoparticles and other nano-scale drug delivery systems. It provides controlled and reproducible mixing of multiple input streams to produce nanomaterials.
5
Opti mem by Thermo Fisher Scientific
Sourced in United States, United Kingdom, Germany, China, Japan, Canada, France, Switzerland, Italy, Australia, Belgium, Spain, Denmark, Ireland, Netherlands, Holy See (Vatican City State), Israel
Opti-MEM is a cell culture medium designed to support the growth and maintenance of a variety of cell lines. It is a serum-reduced formulation that helps to reduce the amount of serum required for cell culture, while still providing the necessary nutrients and growth factors for cell proliferation.
6
Amicon ultra centrifugal filter unit by Merck Group
Sourced in United States, Germany, United Kingdom, Ireland, Morocco
The Amicon Ultra Centrifugal Filter Units are laboratory devices used for the concentration and purification of biological samples, such as proteins, peptides, and nucleic acids. These units employ a centrifugal force to pass the sample through a semi-permeable membrane, which retains the desired molecules while allowing smaller molecules and solvents to pass through. The filtered sample can then be collected for further analysis or processing.
7
Quant it ribogreen rna assay kit by Thermo Fisher Scientific
Sourced in United States, United Kingdom, Australia, Switzerland, France, Germany
The Quant-iT RiboGreen RNA Assay Kit is a fluorescent nucleic acid stain used for the quantitation of RNA in solution. The kit provides a sensitive and accurate method for measuring RNA concentration.
8
V 660 spectrophotometer by Jasco
Sourced in United States, Japan
The V-660 spectrophotometer is a compact and versatile instrument designed for a range of spectroscopic measurements. It features a dual-beam optical system and a wavelength range from 190 nm to 1100 nm, enabling accurate and reliable absorbance, transmittance, and reflectance measurements across a wide spectrum.
9
Dspe peg2000 by Avanti Polar Lipids
Sourced in United States, Germany
DSPE-PEG2000 is a lipid conjugate compound composed of distearoylphosphatidylethanolamine (DSPE) and polyethylene glycol (PEG) with an average molecular weight of 2000 Da. It is a widely used material in the development of liposomal drug delivery systems and other biomedical applications.
10
Johansson monochromator by Bruker
Sourced in United States
The Johansson monochromator is a specialized laboratory instrument designed to isolate a specific wavelength or range of wavelengths from a broader spectrum of electromagnetic radiation. It functions by using a curved crystal to diffract and reflect the desired wavelength while blocking all other wavelengths. The Johansson monochromator is commonly used in various scientific and analytical applications that require the precise selection and isolation of specific wavelengths of light.

More about "Lipid Nanoparticles"

Lipid Nanoparticles (LNPs) are a versatile class of nanomaterials that have gained significant attention in the fields of drug delivery, therapeutics, and biomedical applications.
These nanostructures, typically ranging from 50 to 200 nanometers in size, are composed of lipids arranged in a unique bilayer configuration.
LNPs offer numerous advantages, such as improved drug solubility, enhanced bioavailability, and targeted delivery to specific tissues or cells.
Lipid nanoparticles can also protect sensitive cargo, such as RNA or DNA, from degradation and facilitate their efficient intracellular uptake.
The research on LNPs continues to evolve, with scientists exploring new formulations, surface modifications, and innovative applications to unlock their full potential.
The Zetasizer Nano ZS is a widely used instrument for analyzing the size and zeta potential of LNPs, providing crucial information for their optimization and characterization.
Cholesterol is a common lipid component in LNP formulations, known for its role in membrane fluidity and stability.
Amicon Ultra centrifugal filters and the NanoAssemblr Ignite platform are often utilized in the production and purification of LNPs.
Opti-MEM, a serum-free cell culture medium, is frequently employed for the transfection of cells with LNP-encapsulated nucleic acids.
The Quant-iT RiboGreen RNA Assay Kit and the V-660 spectrophotometer are valuable tools for quantifying the RNA or DNA encapsulation efficiency within LNPs.
DSPE-PEG2000, a polyethylene glycol-derived lipid, is commonly used for LNP surface modification to enhance their stability and circulation time.
Johansson monochromators are sometimes employed in the characterization of LNP properties, such as their optical absorption and fluorescence.
By leveraging these technologies and insights, researchers can streamline the optimization of lipid nanoparticles and advance their applications in various biomedical and therapeutic domains.